Bevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON-Neuroblastoma Trial

Moreno, L. orcid.org/0000-0002-0708-1670, Weston, R. orcid.org/0000-0002-7884-1884, Owens, C. et al. (87 more authors) (2024) Bevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON-Neuroblastoma Trial. Journal of Clinical Oncology, 42 (10). pp. 1135-1145. ISSN 0732-183X

Abstract

Metadata

Item Type: Article
Authors/Creators:
Copyright, Publisher and Additional Information:

© 2024 by American Society of Clinical Oncology. Licensed under the Creative Commons Attribution 4.0 License: http://creativecommons.org/licenses/by/4.0/

Dates:
  • Published: 1 April 2024
  • Published (online): 8 January 2024
  • Accepted: 5 October 2023
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Leeds Institute of Medical Research (LIMR) > Division of Molecular Medicine
Depositing User: Symplectic Publications
Date Deposited: 14 May 2024 09:29
Last Modified: 14 May 2024 09:29
Status: Published
Publisher: American Society of Clinical Oncology
Identification Number: 10.1200/jco.23.00458
Related URLs:
Open Archives Initiative ID (OAI ID):

Export

Statistics